



PolyNovo Limited ABN 96 083 866 862 2/320 Lorimer Street

Port Melbourne VIC Australia 3207

P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099

11 August 2023

# **ASX Announcement**

## **FY23 Results Presentation**

PolyNovo's FY23 results presentation will be live streamed on Wednesday 23 August at 2.00pm AEST.

To access the webcast, shareholders will need to register at the following website prior to the presentation:

Early Registration | PolyNovo - FY23 Results Briefing (choruscall.com)

Shareholders who would like to ask a question are asked to email their question to <u>jan.g@polynovo.com</u> in advance of the event and we will endeavour to answer your question prior to or during the webcast.

Alternatively, shareholders can ask questions during the live webcast by submitting their questions via the webcast platform.

Broker analysts who cover the company have the opportunity to ask questions live.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

### **Further information:**

David Williams	Jan Gielen
Chairman	CFO & Company Secretary
Mobile: + 61 414 383 593	Mobile: +1 904 314 6346

### **About PolyNovo®**

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care. PolyNovo is an Australian based medical device company that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM, NovoSorb MTX) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information see <u>polynovo.com</u>

### About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.